428 related articles for article (PubMed ID: 25100752)
1. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
2. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
4. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
[TBL] [Abstract][Full Text] [Related]
7. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice.
Zhao L; Pan Y; Peng K; Wang Z; Li J; Li D; Tong C; Wang Y; Liang G
J Mol Endocrinol; 2015 Oct; 55(2):119-31. PubMed ID: 26220348
[TBL] [Abstract][Full Text] [Related]
9. A novel 11β-HSD1 inhibitor improves diabesity and osteoblast differentiation.
Park JS; Bae SJ; Choi SW; Son YH; Park SB; Rhee SD; Kim HY; Jung WH; Kang SK; Ahn JH; Kim SH; Kim KY
J Mol Endocrinol; 2014 Apr; 52(2):191-202. PubMed ID: 24444497
[TBL] [Abstract][Full Text] [Related]
10. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
12. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
[TBL] [Abstract][Full Text] [Related]
14. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
Ryu JH; Lee JA; Kim S; Shin YA; Yang J; Han HY; Son HJ; Kim YH; Sa JH; Kim JS; Lee J; Lee J; Park HG
J Med Chem; 2016 Nov; 59(22):10176-10189. PubMed ID: 27798827
[TBL] [Abstract][Full Text] [Related]
16. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
17. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
18. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
20. A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
Oh H; Jeong KH; Han HY; Son HJ; Kim SS; Lee HJ; Kim S; Sa JH; Jun HS; Ryu JH; Choi CS
Eur J Pharmacol; 2015 Dec; 768():139-48. PubMed ID: 26519792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
